AptarGroup (ATR) investor relations material

Strategic priorities and value creation

• Focus on profitable growth through innovation, operational efficiency, and disciplined capital allocation.

• Raised ROIC target by 100 basis points to 12–14% and increased dividend by nearly 7%.

• Emphasis on sustainability, global reach, and leveraging technology platforms across all segments.

• M&A remains a key growth lever, with bolt-on acquisitions and accretive deals complementing organic expansion.

• Strong balance sheet and liquidity provide flexibility for future investments and growth initiatives.

Financial performance and long-term targets

• Achieved 8% revenue growth and nearly 50% adjusted EPS growth over two years, with adjusted EBITDA margin at 21.6% in 2024.

• Free cash flow up 87% and returns up 40% in the same period.

• Long-term targets: 4–7% core sales growth, 21–23% EBITDA margin, 12–14% ROIC, and 30–40% dividend payout ratio.

• $110M in structural cost savings delivered since 2022, with SG&A and labor productivity improvements.

• Free cash flow expected to improve as capital intensity moderates and earnings grow.

Segment highlights and growth drivers

• Pharma: Pipeline launches add 7–10% of revenue annually, with focus on injectables, digital health, and regulatory services.

• Beauty: Improved cost base, regional expansion, and innovation pipeline drive 3–6% core sales growth.

• Closures: Achieved $700M in sales, targeting 4–7% core sales growth and 16–18% EBITDA margin.

• All segments emphasize operational efficiency, cost management, and regional expansion, especially in high-growth markets like Asia and LATAM.

• Innovation in sustainable packaging and premium dispensing solutions is a key differentiator.